SEYSARA Drug Patent Profile
✉ Email this page to a colleague
When do Seysara patents expire, and when can generic versions of Seysara launch?
Seysara is a drug marketed by Almirall and is included in one NDA. There are four patents protecting this drug.
This drug has seventy-one patent family members in twenty countries.
The generic ingredient in SEYSARA is sarecycline hydrochloride. One supplier is listed for this compound. Additional details are available on the sarecycline hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Seysara
Seysara was eligible for patent challenges on October 1, 2022.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 9, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for SEYSARA
| International Patents: | 71 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 62 |
| Clinical Trials: | 1 |
| Patent Applications: | 76 |
| Drug Prices: | Drug price information for SEYSARA |
| What excipients (inactive ingredients) are in SEYSARA? | SEYSARA excipients list |
| DailyMed Link: | SEYSARA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SEYSARA
Generic Entry Date for SEYSARA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for SEYSARA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Derm Research, PLLC | Phase 4 |
Pharmacology for SEYSARA
| Drug Class | Tetracycline-class Drug |
| Mechanism of Action | P-Glycoprotein Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for SEYSARA
US Patents and Regulatory Information for SEYSARA
SEYSARA is protected by five US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SEYSARA is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SEYSARA
Substituted tetracycline compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
Substituted tetracycline compounds for treatment of inflammatory skin disorders
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(met- hyl)amino)-methyl] acid amide and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(met- hyl)amino)-methyl] acid amide and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
Substituted tetracycline compounds for treatment of inflammatory skin disorders
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-001 | Oct 1, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-002 | Oct 1, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-001 | Oct 1, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-003 | Oct 1, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SEYSARA
When does loss-of-exclusivity occur for SEYSARA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Canada
Patent: 35876
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0191295
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 07003
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 07003
Estimated Expiration: ⤷ Try a Trial
Patent: 74908
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 44536
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 74572
Estimated Expiration: ⤷ Try a Trial
Patent: 76082
Estimated Expiration: ⤷ Try a Trial
Patent: 14520077
Estimated Expiration: ⤷ Try a Trial
Patent: 17132775
Estimated Expiration: ⤷ Try a Trial
Patent: 19142867
Estimated Expiration: ⤷ Try a Trial
Patent: 21098695
Estimated Expiration: ⤷ Try a Trial
Patent: 23093519
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 07003
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 07003
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 07003
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 07003
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 39626
Estimated Expiration: ⤷ Try a Trial
Turkey
Patent: 1911086
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SEYSARA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2007338681 | Substituted tetracycline compounds for treatment of inflammatory skin disorders | ⤷ Try a Trial |
| Japan | 2023093519 | （４Ｓ，４ＡＳ，５ＡＲ，１２ＡＳ）－４－ジメチルアミノ－３，１０，１２，１２Ａ－テトラヒドロキシ－７－［（メトキシ（メチル）アミノ）－メチル］－１，１１－ジオキソ－１，４，４Ａ，５，５Ａ，６，１１，１２Ａ－オクタヒドロ－ナフタセン－２－カルボン酸アミドの結晶塩及びそれを使用する方法 (CRYSTALLINE SALTS OF (4S,4AS,5AR,12AS)-4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7-[(METHOXY(METHYL)AMINO)-METHYL]-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE, AND METHODS OF USING THE SAME) | ⤷ Try a Trial |
| Hong Kong | 1170218 | 治療細菌、病毒及寄生蟲感染的四環素族衍生物 (TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS) | ⤷ Try a Trial |
| Japan | 6061897 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
